Relevant bibliographies by topics / Treatment of inflammatory disease / Journal articles

Journal articles on the topic 'Treatment of inflammatory disease'

To see the other types of publications on this topic, follow the link: Treatment of inflammatory disease.
Author: Grafiati
Published: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Treatment of inflammatory disease.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Fichna, Jakub. "Inflammatory bowel disease treatment." Pharmacological Reports 68, no. 4 (August 2016): 787–88. http://dx.doi.org/10.1016/j.pharep.2016.05.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Leu, Sheng. "A Brief Review Chronic Inflammatory Autoimmune Disease: Multiple Sclerosis Pathogenesis and Treatment." Neuroscience and Neurological Surgery 1, no. 4 (November 22, 2017): 01–03. http://dx.doi.org/10.31579/2578-8868/016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yadollahpour, Ali. "A Brief Review Chronic Inflammatory Autoimmune Disease: Multiple Sclerosis Pathogenesis and Treatment." Neuroscience and Neurological Surgery 1, no. 4 (November 22, 2017): 01–03. http://dx.doi.org/10.31579/2578-8868/023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

SANTOS, Rachael Miranda dos, Ana Teresa Pugas CARVALHO, Kelly dos Santos SILVA, Selma Petra Chaves SÁ, Aparecida Helena dos SANTOS, and Millene Ramos SANDINHA. "INFLAMMATORY BOWEL DISEASE: OUTPATIENT TREATMENT PROFILE." Arquivos de Gastroenterologia 54, no. 2 (March 16, 2017): 96–100. http://dx.doi.org/10.1590/s0004-2803.201700000-01.

Full text
Abstract:
ABSTRACT BACKGROUND Crohn’s disease and ulcerative colitis are the two major forms of inflammatory bowel disease. The incidence and prevalence of both conditions have increased and are progressively increasing. These diseases are frequently recurrent and clinically highly severe. In Brazil, the lack of epidemiological data related to such diseases has left these patients in a vulnerable state and contributed to increased morbidity. OBJECTIVE To describe the profiles of patients with inflammatory bowel disease treated in an outpatient service in Brazil. METHODS This descriptive, exploratory, and retrospective documentary study with a quantitative approach was performed in an outpatient treatment service for inflammatory bowel disease, at a university polyclinic located in Rio de Janeiro, Brazil, from May to July 2016. The study included 556 patients and was approved by the research ethics committee of the institution (CAAE no. 55179316.6.0000.5259/2016). RESULTS The data showed a high prevalence of inflammatory bowel disease in white female patients. Crohn’s disease was diagnosed in more patients than was ulcerative colitis; the ileocolon was the most commonly affected location in patients with Crohn’s disease. The stenotic phenotype was prevalent in patients with Crohn’s disease. CONCLUSION The prevalence of the stenotic phenotype in Crohn’s disease in relation to others demonstrates the need for further investigations in this field of study in Brazil. In conclusion, the data showed that the epidemiologic profile of the study population is similar to that published in the national and international literature.
APA, Harvard, Vancouver, ISO, and other styles
5

Eschenbach, D. "Treatment of Pelvic Inflammatory Disease." Clinical Infectious Diseases 44, no. 7 (April 1, 2007): 961–63. http://dx.doi.org/10.1086/512200.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Quentin, R., and J. Lansac. "Pelvic inflammatory disease: medical treatment." European Journal of Obstetrics & Gynecology and Reproductive Biology 92, no. 2 (October 2000): 189–92. http://dx.doi.org/10.1016/s0301-2115(99)00279-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Watanabe, Mamoru, Daisuke Kubota, Masakazu Nagahori, and Takanori Kanai. "Treatment of Inflammatory Immunologic Disease 1. Leukocytapheresis for Inflammatory Immunologic Disease (Tentative)." Internal Medicine 46, no. 16 (2007): 1305–6. http://dx.doi.org/10.2169/internalmedicine.46.1911.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Teml, Alexander, Elke Schaeffeler, Klaus R. Herrlinger, Ulrich Klotz, and Matthias Schwab. "Thiopurine Treatment in Inflammatory Bowel Disease." Clinical Pharmacokinetics 46, no. 3 (2007): 187–208. http://dx.doi.org/10.2165/00003088-200746030-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gardiner, Sharon J., Evan J. Begg, Ashis Sau, Anthony Marinaki, Richard B. Gearry, and Murray L. Barclay. "Thiopurine Treatment in??Inflammatory Bowel??Disease." Clinical Pharmacokinetics 46, no. 9 (2007): 803–4. http://dx.doi.org/10.2165/00003088-200746090-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Price, Ronald L. "Surgical Treatment of Ocular Inflammatory Disease." Journal of Pediatric Ophthalmology & Strabismus 26, no. 2 (March 1989): 75. http://dx.doi.org/10.3928/0191-3913-19890301-08.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Balakshina, N. G., and L. I. Kokh. "Surgical treatment of pelvic inflammatory disease." Bulletin of Siberian Medicine 9, no. 1 (February 28, 2010): 70–75. http://dx.doi.org/10.20538/1682-0363-2010-1-70-75.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Lee, Kwang Jae. "Pharmacologic treatment for inflammatory bowel disease." Journal of the Korean Medical Association 58, no. 1 (2015): 57. http://dx.doi.org/10.5124/jkma.2015.58.1.57.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Park, Jong Beom, and Hyo Jong Kim. "Medical Treatment of Inflammatory Bowel Disease." Journal of the Korean Medical Association 49, no. 12 (2006): 1164. http://dx.doi.org/10.5124/jkma.2006.49.12.1164.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Dew, M. J. "Medical treatment of inflammatory bowel disease." Current Opinion in Gastroenterology 3, no. 3 (May 1987): 449–59. http://dx.doi.org/10.1097/00001574-198705000-00014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Peña, A. S. "Medical treatment of inflammatory bowel disease." Current Opinion in Gastroenterology 5, no. 4 (August 1989): 487–94. http://dx.doi.org/10.1097/00001574-198908000-00002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Present, D. H. "Medical treatment of inflammatory bowel disease." Current Opinion in Gastroenterology 6, no. 4 (August 1990): 536–42. http://dx.doi.org/10.1097/00001574-199008000-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Campieri, M., P. Gionchetti, A. Belluzzi, C. Brignola, M. Miglioli, and L. Barbara. "Medical treatment of inflammatory bowel disease." Current Opinion in Gastroenterology 8, no. 4 (August 1992): 663–75. http://dx.doi.org/10.1097/00001574-199208000-00016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Fazio, Victor W., and Scott A. Strong. "Surgical treatment of inflammatory bowel disease." Current Opinion in Gastroenterology 13, no. 4 (July 1997): 317–24. http://dx.doi.org/10.1097/00001574-199707000-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Strong, Scott A., and Victor W. Fazio. "Surgical treatment of inflammatory bowel disease." Current Opinion in Gastroenterology 15, no. 4 (July 1999): 326. http://dx.doi.org/10.1097/00001574-199907000-00009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Strong, Scott A. "Surgical treatment of inflammatory bowel disease." Current Opinion in Gastroenterology 18, no. 4 (July 2002): 441–46. http://dx.doi.org/10.1097/00001574-200207000-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Shanahan, F., and S. Targan. "Medical Treatment of Inflammatory Bowel Disease." Annual Review of Medicine 43, no. 1 (February 1992): 125–33. http://dx.doi.org/10.1146/annurev.me.43.020192.001013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Sweet, Richard L. "Treatment of Acute Pelvic Inflammatory Disease." Infectious Diseases in Obstetrics and Gynecology 2011 (2011): 1–13. http://dx.doi.org/10.1155/2011/561909.

Full text
Abstract:
Pelvic inflammatory disease (PID), one of the most common infections in nonpregnant women of reproductive age, remains an important public health problem. It is associated with major long-term sequelae, including tubal factor infertility, ectopic pregnancy, and chronic pelvic pain. In addition, treatment of acute PID and its complications incurs substantial health care costs. Prevention of these long-term sequelae is dependent upon development of treatment strategies based on knowledge of the microbiologic etiology of acute PID. It is well accepted that acute PID is a polymicrobic infection. The sexually transmitted organisms,Neisseria gonorrhoeaeandChlamydia trachomatis, are present in many cases, and microorganisms comprising the endogenous vaginal and cervical flora are frequently associated with PID. This includes anaerobic and facultative bacteria, similar to those associated with bacterial vaginosis. Genital tract mycoplasmas, most importantlyMycoplasma genitalium, have recently also been implicated as a cause of acute PID. As a consequence, treatment regimens for acute PID should provide broad spectrum coverage that is effective against these microorganisms.
APA, Harvard, Vancouver, ISO, and other styles
23

Pollak, Marcia. "Psychoanalytic Treatment of Inflammatory Gut Disease." Contemporary Psychology: A Journal of Reviews 41, no. 5 (May 1996): 480–81. http://dx.doi.org/10.1037/004454.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Prayoonwiwat, Naraporn, and Sasitorn Siritho. "Early treatment of inflammatory demyelinating disease." Nature Reviews Neurology 9, no. 5 (April 16, 2013): 246–47. http://dx.doi.org/10.1038/nrneurol.2013.59.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Endres, Stefan, Reinhard Lorenz, and Klaus Loeschke. "Lipid treatment of inflammatory bowel disease." Current Opinion in Clinical Nutrition and Metabolic Care 2, no. 2 (March 1999): 117–20. http://dx.doi.org/10.1097/00075197-199903000-00004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Herman, Margot L., and Sunanda V. Kane. "Treatment Nonadherence in Inflammatory Bowel Disease." Inflammatory Bowel Diseases 21, no. 12 (December 2015): 2979–84. http://dx.doi.org/10.1097/mib.0000000000000581.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

SANDBORN, WILLIAM J., and WILLIAM J. TREMAINE. "Cyclosporine Treatment of Inflammatory Bowel Disease." Mayo Clinic Proceedings 67, no. 10 (October 1992): 981–90. http://dx.doi.org/10.1016/s0025-6196(12)60930-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Lindor, Keith D. "Inflammatory Bowel Disease: Diagnosis and Treatment." Mayo Clinic Proceedings 67, no. 10 (October 1992): 1014–15. http://dx.doi.org/10.1016/s0025-6196(12)60941-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Kahng, Kim U., and Joel J. Roslyn. "Surgical treatment of inflammatory bowel disease." Medical Clinics of North America 78, no. 6 (November 1994): 1427–41. http://dx.doi.org/10.1016/s0025-7125(16)30109-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Pithadia, Anand B., and Sunita Jain. "Treatment of inflammatory bowel disease (IBD)." Pharmacological Reports 63, no. 3 (May 2011): 629–42. http://dx.doi.org/10.1016/s1734-1140(11)70575-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Magro, Fernando, Gonçalo Cordeiro, Andreia Martins Dias, and Maria Manuela Estevinho. "Inflammatory Bowel Disease – Non-biological treatment." Pharmacological Research 160 (October 2020): 105075. http://dx.doi.org/10.1016/j.phrs.2020.105075.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Schwartz, David A., and Brad E. Maltz. "Treatment of Fistulizing Inflammatory Bowel Disease." Medical Clinics of North America 94, no. 1 (January 2010): 19–34. http://dx.doi.org/10.1016/j.mcna.2009.08.020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Leone, Charles R., and William C. Lloyd. "Treatment Protocol for Orbital Inflammatory Disease." Ophthalmology 92, no. 10 (October 1985): 1325–31. http://dx.doi.org/10.1016/s0161-6420(85)33854-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

MacDermott, Richard P., and Andrew Conn. "Inflammatory bowel disease: Diagnosis and treatment." Gastroenterology 102, no. 2 (February 1992): 738. http://dx.doi.org/10.1016/0016-5085(92)90137-n.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Sachar, David B. "Cyclosporine Treatment for Inflammatory Bowel Disease." New England Journal of Medicine 321, no. 13 (September 28, 1989): 894–96. http://dx.doi.org/10.1056/nejm198909283211309.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Schwartz, David A., and Brad E. Maltz. "Treatment of Fistulizing Inflammatory Bowel Disease." Gastroenterology Clinics of North America 38, no. 4 (December 2009): 595–610. http://dx.doi.org/10.1016/j.gtc.2009.07.009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

&NA;. "Treatment Protocol for Orbital Inflammatory Disease." Ophthalmic Plastic & Reconstructive Surgery 2, no. 1 (1986): 55. http://dx.doi.org/10.1097/00002341-198601040-00044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Sweet, Richard L. "Treatment strategies for pelvic inflammatory disease." Expert Opinion on Pharmacotherapy 10, no. 5 (April 2009): 823–37. http://dx.doi.org/10.1517/14656560902823816.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Hodgson, H. J. F. "Inflammatory bowel disease - diagnosis and treatment." Gut 33, no. 3 (March 1, 1992): 425. http://dx.doi.org/10.1136/gut.33.3.425-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Raizman, Michael. "Surgical Treatment of Ocular Inflammatory Disease." Archives of Ophthalmology 107, no. 5 (May 1, 1989): 650. http://dx.doi.org/10.1001/archopht.1989.01070010668020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Grimes, David A. "Antibiotic Treatment of Pelvic Inflammatory Disease." JAMA 256, no. 23 (December 19, 1986): 3223. http://dx.doi.org/10.1001/jama.1986.03380230047023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Sellin, Joseph. "Treatment targets in inflammatory bowel disease." Advanced Drug Delivery Reviews 57, no. 2 (January 2005): 217–18. http://dx.doi.org/10.1016/j.addr.2004.08.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Matsumoto, Takayuki. "Treatment of Inflammatory Immunologic Disease 2. Anti-Cytokine Therapies in Inflammatory Bowel Disease." Internal Medicine 46, no. 16 (2007): 1307–9. http://dx.doi.org/10.2169/internalmedicine.46.1912.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Melestean-Bratu, Madalina-Ioana, Antoine Edu, Mihaela Bujor, Stelian Conci, Florin Isopescu, Radu Mateescu, Mihai Dumitrascu, Florica Sandru, Andreea Carp-Veliscu, and Claudia Mehedintu. "Pelvic inflammatory disease." Romanian Journal of Medical Practice 16, S6 (December 15, 2021): 5–7. http://dx.doi.org/10.37897/rjmp.2021.s6.1.

Full text
Abstract:
Pelvic inflammatory disease (PID) is a very common condition among women of reproductive age. It is also a common reason for presenting to the emergency room. Although it often presents with mild symptoms, it is very important to consider it in any sexually active patient in order to start treatment as soon as possible and avoid complications.
APA, Harvard, Vancouver, ISO, and other styles
45

Wei, Yanting We, Hongning Su, Dandan Geng, Weimin Huo, Miao Zhou, Jiajia Li, and Ke He. "Clinical effect of Hongteng decoction combined with levofloxacin in the treatment of chronic pelvic inflammatory disease and its effect on inflammatory factors." ISP Medicine 3, no. 1 (January 1, 2021): 1–8. http://dx.doi.org/10.52274/ispmed20210307.

Full text
Abstract:
Objective: To explore the clinical therapeutic effect of Hongteng decoction combined with levofloxacin on chronic pelvic inflammatory disease (CPID) patients and its effect on the expression of inflammatory factors. Methods: 72 patients with CPID who were diagnosed and treated in the Fourth Hospital of Shijiazhuang City from January 2020 to December 2020 were selected and randomly divided into observation group (n = 36) and control group (n = 36). The control group was treated with levofloxacin and the observation group was treated with Hongteng decoction retention enema on the basis of the control group. Both groups were treated continuously for 2 courses. The clinical therapeutic effects of the two groups were compared, and the changes of related inflammatory indexes such as interleukin-2 (IL-2), interleukin-10 (IL-10), C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α) were compared between the two groups before and after treatment. The score of quality of life and the occurrence of adverse reactions before treatment were compared. Results: The total effective rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P<0.05). The inflammatory indexes of IL-2, IL-10, CRP and TNF-α in 2 groups before treatment were compared, and there was no statistical significance (P>0.05). After treatment, the expression of IL-2 and IL-10 in the observation group was higher than that in the control group, and the expression of CRP and TNF-α was lower than that in the control group, with statistical significance (P<0.05). There were no significant differences in physical pain, life function, social function and mental health scores between the two groups before treatment (P>0.05). After treatment, scores of physical pain, life function, social function and mental health in the observation group were higher than those in the control group, and the differences were statistically significant (P<0.05). After treatment, there was no significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05). Conclusion: Hongteng decoction combined with levofloxacin has definite efficacy in the treatment of CPID, which can effectively improve the clinical symptoms of patients and inhibit inflammatory response, and is worthy of clinical promotion.
APA, Harvard, Vancouver, ISO, and other styles
46

Hodson, Alexander. "Pelvic Inflammatory Disease." InnovAiT: Education and inspiration for general practice 2, no. 9 (August 26, 2009): 517–21. http://dx.doi.org/10.1093/innovait/inp082.

Full text
Abstract:
Pelvic inflammatory disease (PID), infection and inflammation of the upper female genital tract, is a common condition managed by General Practitioners (GPs). It accounts for one in 60 consultations in women of reproductive age. Early diagnosis, management and, if necessary, referral is essential to help prevent serious long-term complications such as ectopic pregnancy, infertility and chronic pelvic pain. This article outlines the causes, clinical features, treatment and follow-up of PID.
APA, Harvard, Vancouver, ISO, and other styles
47

HUSNÍK, R., J. KLIMEŠ, K. TOMANOVÁ, J. SMOLA, R. HALOUZKA, F. TICHÝ, and J. BRÁZDIL. "Lawsonia intracellularis in a dog with inflammatory bowel disease." Veterinární Medicína 48, No. 5 (March 30, 2012): 141–45. http://dx.doi.org/10.17221/5761-vetmed.

Full text
Abstract:
A two-year-old male German short-haired pointer was presented with a 1.5-year history of intermittent small-bowel diarrhoea. Inflammatory bowel disease (chronic lymphocytic-plasmacytic gastritis, enteritis and colitis) was diagnosed on the basis of histological examination of biopsies obtained on repeated endoscopy and by exclusion of other possible causes. Warthin-Starry silver staining of stomach mucosa revealed the presence of gastric spiral organisms. The evidence of L. intracellularis was provided by a positive nested polymerase chain reaction in one biopsy of duodenal mucosa and in one rectal smear. In 5 blood sera collected over a period of 8 months the IgG antibodies to L. intracellularis were found by an indirect fluorescent antibody test. Treatment with oral prednisone led only to a temporary improvement.
APA, Harvard, Vancouver, ISO, and other styles
48

Rakha, Serena S. "Pelvic inflammatory disease." InnovAiT: Education and inspiration for general practice 11, no. 4 (March 2, 2018): 198–200. http://dx.doi.org/10.1177/1755738017750998.

Full text
Abstract:
Pelvic inflammatory disease (PID) is a generalised term that describes infection of the upper genital tract in women. It is commonly caused by the sexually transmitted infections Chlamydia Trachomatis and Neisseria Gonorrhoea. Clinical features of PID include pelvic pain, deep dyspareunia, cervical motion tenderness and adnexal tenderness. Complications include infertility, ectopic pregnancy and chronic pelvic pain. Therefore, it is important for GPs to have a high index of suspicion when women present with symptoms of PID and to initiate antibiotic treatment before vaginal swab results are known.
APA, Harvard, Vancouver, ISO, and other styles
49

Gargallo-Puyuelo, Carla, Erika Alfambra, Jose García-Erce, and Fernando Gomollon. "Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm." Nutrients 10, no. 12 (December 11, 2018): 1959. http://dx.doi.org/10.3390/nu10121959.

Full text
Abstract:
Iron plays a key role in many physiological processes; cells need a very exact quantity of iron. In patients with inflammatory bowel disease, anaemia is a unique example of multifactorial origins, frequently being the result of a combination of iron deficiency and anaemia of chronic disease. The main cause of iron deficiency is the activity of the disease. Therefore, the first aim should be to reach complete clinical remission. The iron supplementation route should be determined according to symptoms, severity of anaemia and taking into account comorbidities and individual risks. Oral iron can only be used in patients with mild anaemia, whose disease is inactive and who have not been previously intolerant to oral iron. Intravenous iron should be the first line treatment in patients with moderate-severe anaemia, in patients with active disease, in patients with poor tolerance to oral iron and when erythropoietin agents or a fast response is needed. Erythropoietin is used in a few patients with anaemia to overcome functional iron deficiency, and blood transfusion is being restricted to refractory cases or acute life-threatening situations.
APA, Harvard, Vancouver, ISO, and other styles
50

Brenner, Erica J., and Millie D. Long. "Diagnosis and treatment of dermatologic diseases in inflammatory bowel disease." Current Opinion in Gastroenterology 35, no. 4 (July 2019): 330–36. http://dx.doi.org/10.1097/mog.0000000000000538.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Treatment of inflammatory disease' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography